{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344608","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2026-08-11T20:07:16+00:00","discovered_at":"2026-08-11T20:08:04.396064+00:00","generated_at":"2026-08-11T20:08:28.932369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BBOT reports Q2 2026 net loss of $56.5M; cash runway into 2028","bullets":["Net loss widened to $56.5M in Q2 2026 vs $28.4M in Q2 2025; R&D up to $49.2M from $27.4M.","G&A rose to $11.0M from $2.7M, reflecting standalone operations, de-SPAC, and one-time severance.","Cash, equivalents and marketable securities $344.1M as of June 30, 2026; expected runway into 2028.","Initiated dosing of BBO-11818 + cetuximab and BBO-11818 + BBO-10203 combos; also BBO-8520 + BBO-10203."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344608","json":"https://secwatch.observer/filing/0001193125-26-344608.json","markdown":"https://secwatch.observer/filing/0001193125-26-344608.md","text":"https://secwatch.observer/filing/0001193125-26-344608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526344608/0001193125-26-344608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526344608/bbot-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:08:28.932369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}